

Immaculada Margarit y Ros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/906134/publications.pdf>

Version: 2024-02-01

24
papers

1,670
citations

471509

17
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1846
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. <i>Science</i> , 2005, 309, 148-150.	12.6	497
2	<i>Streptococcus agalactiae</i> clones infecting humans were selected and fixed through the extensive use of tetracycline. <i>Nature Communications</i> , 2014, 5, 4544.	12.8	208
3	Preventing Bacterial Infections with Pilus-Based Vaccines: the Group B Streptococcus Paradigm. <i>Journal of Infectious Diseases</i> , 2009, 199, 108-115.	4.0	201
4	Identification of novel genomic islands coding for antigenic pilus-like structures in <i>Streptococcus agalactiae</i> . <i>Molecular Microbiology</i> , 2006, 61, 126-141.	2.5	190
5	Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. <i>Vaccine</i> , 2017, 35, 361-368.	3.8	96
6	Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci. <i>International Journal of Medical Microbiology</i> , 2011, 301, 240-251.	3.6	64
7	The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera. <i>Clinical Infectious Diseases</i> , 2016, 63, 746-753.	5.8	53
8	Structure of the Type IX Group B Streptococcus Capsular Polysaccharide and Its Evolutionary Relationship with Types V and VII. <i>Journal of Biological Chemistry</i> , 2014, 289, 23437-23448.	3.4	48
9	Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. <i>FASEB Journal</i> , 2009, 23, 3100-3112.	0.5	47
10	Genomic Analysis Reveals Multi-Drug Resistance Clusters in Group B Streptococcus CC17 Hypervirulent Isolates Causing Neonatal Invasive Disease in Southern Mainland China. <i>Frontiers in Microbiology</i> , 2016, 7, 1265.	3.5	40
11	Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. <i>Vaccine</i> , 2020, 38, 6930-6940.	3.8	34
12	Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1387-1399.	4.4	28
13	A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. <i>Journal of Immunological Methods</i> , 2012, 378, 11-19.	1.4	22
14	Contribution of pilus type 2b to invasive disease caused by a <i>Streptococcus agalactiae</i> ST-17 strain. <i>BMC Microbiology</i> , 2017, 17, 148.	3.3	22
15	Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. <i>Journal of Infection</i> , 2018, 76, 449-456.	3.3	22
16	Immune Response to Invasive Group B Streptococcus Disease in Adults. <i>Emerging Infectious Diseases</i> , 2016, 22, 1877-1883.	4.3	18
17	Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models. <i>Scientific Reports</i> , 2018, 8, 2593.	3.3	18
18	Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2570-2579.	5.8	18

#	ARTICLE	IF	CITATIONS
19	The Group B <i>Streptococcus</i> Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways. <i>Journal of Immunology</i> , 2016, 196, 385-394.	0.8	15
20	Fighting Antibiotic-Resistant <i>Klebsiella pneumoniae</i> with "Sweet" Immune Targets. <i>MBio</i> , 2018, 9, .	4.1	14
21	Group B <i>Streptococcus</i> chimeric capsular polysaccharides as novel multivalent vaccine candidates. <i>Glycoconjugate Journal</i> , 2021, 38, 447-457.	2.7	5
22	Novel Multiplex Immunoassays for Quantification of IgG against Group B <i>Streptococcus</i> Capsular Polysaccharides in Human Sera. <i>MSphere</i> , 2019, 4, .	2.9	4
23	The <i>Streptococcus agalactiae</i> complement interfering protein combines multiple complement inhibitory mechanisms by interacting with both C4 and C3 ligands. <i>FASEB Journal</i> , 2019, 33, 4448-4457.	0.5	4
24	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B <i>Streptococcus</i> intranasal infection. <i>Scientific Reports</i> , 2021, 11, 21384.	3.3	2